Clinical Trial Update: Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675) [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating SCH 900271 in primary hypercholesterolemia and mixed hyperlipidemia completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Hyperlipidemia

Drugs mentioned

• SCH 900271

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Primary Hypercholesterolemia, Mixed Hyperlipidemia | Phase 2 | Status: COMPLETED | Results posted: 2016-04-12